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Abstract Transanal total mesorectal excision (TaTME)
has been developed to improve quality of TME for patients
with mid and low rectal cancer. However, despite enthu-
siastic uptake and teaching facilities, concern exists for
safe introduction. TaTME is a complex procedure and
potentially a learning curve will hamper clinical outcome.
With this systematic review, we aim to provide data
regarding morbidity and safety of TaTME. A systematic
literature search was performed in MEDLINE (PubMed),
EMBASE (Ovid) and Cochrane Library. Case reports,
cohort series and comparative series on TaTME for rectal
cancer were included. To evaluate a potential effect of case
volume, low-volume centres (n B 30 total volume) were
compared with high-volume centres (n[ 30 total volume).
Thirty-three studies were identified (three case reports, 25
case series, five comparative studies), including 794
patients. Conversion was performed in 3.0% of the pro-
cedures. The complication rate was 40.3, and 11.5% were
major complications. The quality of the mesorectum was
‘‘complete’’ in 87.6%, and the circumferential resection
margin (CRM) was involved in 4.7%. In low- versus high-
volume centres, the conversion rate was 4.3 versus 2.7%,
and major complication rates were 12.2 versus 10.5%,
respectively. TME quality was ‘‘complete’’ in 80.5 versus
89.7%, and CRM involvement was 4.8 and 4.5% in low-
versus high-volume centres, respectively. TaTME for mid
and low rectal cancer is a promising technique; however, it
is associated with considerable morbidity. Safe imple-
mentation of the TaTME should include proctoring and
quality assurance preferably within a trial setting.
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Introduction
Transanal total mesorectal excision (TaTME) has had
tremendous attention since its introduction in 2010 by the
group of Lacy [1]. The TaTME technique has been
developed to improve the quality of the TME procedure for
patients with mid and low rectal cancer. In TaTME, the low
pelvic mesorectum is approached through the anus using a
laparoscopic single-port platform. Potentially, TaTME
facilitates the quality of dissection and decreases the need
for definitive colostomies and conversions to open tech-
nique. Moreover, the TaTME technique aims to achieve
higher rates of complete specimens, better visual determi-
nation of the distal margin and lower rates of involved
circumferential resection margin (CRM) compared to
abdominal TME. Especially in low rectal cancer surgery,
relative higher rates of incomplete specimens and higher
rates of CRM involvement have been reported compared to
tumours located in the upper rectum [2–11]. Mid and low
rectal cancer are associated with worse outcome when
compared to high rectal cancer due to the difficult access of
the lower pelvis. The innovative TaTME technique has the
potential to improve these results. However, randomised
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clinical trials evaluating this new technique are lacking
[12–14].
Despite the potential benefits, concern exists for uncon-
trolled widespread adaptation. TaTME is a complex proce-
dure and a learning curve might influence initial clinical
results. Since poor surgical quality in rectal cancer is asso-
ciated with poor outcome, quality assurance of the new
surgical technique seems plausible. Early adaptors of the
technique have shown favourable results, but new serious
complications have also been published [15–18]. Urethra
injury or pelvic side wall injury with bleeding and nerve
damage has not been documented for the conventional low
anterior resection (LAR) [2–11]. In addition, increased
bacterial load as is observed after TaTME might induce the
occurrence of presacral abscesses [19]. Most importantly,
data regarding oncological outcome after TaTME for mid
and low rectal cancer are still scarce [12–18]. Although the
aim is to perform resection with intact specimen, rectal wall
perforations are observed which can potentially result in
tumour spill [1, 15]. Concern exists if luminal contamination
with tumour cells of the pelvis results in more recurrences
despite a negative resection margin and good quality speci-
men. In addition to oncological outcome, the long-term
functional outcome of the procedure has to be awaited.
Potentially, lower anastomosis results in worse functional
outcome compared to abdominal laparoscopic TME.
With this systematic review, we aim to provide a com-
prehensiveoverviewof the current data regarding safety of the
TaTMEprocedure reporting on perioperative and oncological
results with specific focus on adverse events and outcomes.
Materials and methods
Search strategy
This systematic review was conducted according to the
PreferredReporting Items for Systematic Reviews andMeta-
Analysis (PRISMA) guidelines [20]. MEDLINE (PubMed),
EMBASE (Ovid) and the Cochrane Library were searched
systematically. The search period was from January 1 2005
until July 1 2016. The following search terms were used:
(((excision*[tiab] OR resection*[tiab] OR TME[tiab] OR
TaTME[tiab] OR TAMIS[tiab] OR NOTES[tiab] OR proc-
tectom*[tiab]) AND (transanal*[tiab] OR trans-anal*[tiab]))
OR ((excision*[ot] OR resection*[ot] OR TME[ot] OR
TaTME[ot] OR TAMIS[ot] OR NOTES[ot] OR proctec-
tom*[ot]) AND (transanal*[ot] OR trans-anal*[ot]))) AND
((((‘‘Neoplasms’’[Mesh] OR neoplas*[tw] OR tumor*[tw]
OR tumour*[tw] OR cancer*[tw] OR malignan*[tw] OR
oncolog*[tw] OR carcinom*[tw] OR adenocarcinom*[tw])
AND (‘‘Rectum’’[Mesh] OR rectum[tiab] OR rectal[tiab]
OR colorect*[tiab] OR mesorect*[tiab])) AND
(‘‘surgery’’[Subheading] OR surgery[tiab] OR surgical[tiab]
OR operati*[tiab])) OR (‘‘Rectal Neoplasms/surgery’’
[Mesh:noexp])). References of the retrieved papers were
screened to search for additional reports.
Inclusion and exclusion criteria
Published clinical studies on TaTME for rectal cancer
reporting clinical and pathological outcomes were included.
Case reports, cohort series and comparative series were eli-
gible. Abstracts, reports with no peer-reviewed data and
reports on robotic TaTMEwere excluded. No restriction was
made based on included number of patients. Only articles in
European languages were included. Two reviewers inde-
pendently assessed all titles, abstracts and full texts for
potential inclusion. When required, a third reviewer was
consulted. Included articles based on full text were checked
for overlapping data with other studies. Studies with poten-
tial overlapping patient populations were excluded for the
overall analysis and subanalysis regarding volume.
Endpoints and data extraction
The primary endpoints of this study were short-term mor-
bidity and specimen outcome. The following data were col-
lected from included studies: first author, year of publication,
number of patients, patient and tumour characteristics (gen-
der, BMI, age, ASA classification, tumour distance, clinical
TNM stage, neoadjuvant therapy), surgical details (operative
time, type of anastomosis, use of diverting ileostomy,
approach with synchronous abdominal and transanal resec-
tion, intraoperative complications, conversion rate), pathol-
ogy outcomes (TME quality, involvement of CRM,
involvement of distal resectionmargin, pathological T and N
stage) and post-operative outcomes (hospital stay, post-op-
erative complications, 30-day mortality rate and local and
distant recurrence rates after follow-up of 12 months).
Heterogeneity in data on the height of tumour restricted
data evaluation. Therefore, height was adjusted using
international accepted definitions for anal verge (baseline
0 cm), dentate line (?1.9 cm) and anorectal junction
(?4 cm) [21–23]. Post-operative complications were
reported as classified by Clavien–Dindo [24]. Minor com-
plications were defined as complications needing non-in-
vasive treatment (Clavien–Dindo classification I or II), and
major complications were defined as complications need-
ing invasive treatment (Clavien–Dindo C III).
Subanalysis low-volume centres versus high-volume
centres
To identify a possible difference in outcome depending on
the volume in the TaTME technique, subanalysis of all
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variables was performed comparing low-volume centres
(n B 30 total volume) with high-volume centres (n[ 30
total volume) and excluding potential (partial) duplicates of
cases in publications by centres that published multiple
cohort series [25].
Statistical analysis
For all participating patients from the different included
studies, data for several variables were pooled in a way as
if the patients participated in one study. The mean of the
variable of interest of each included study was multiplied
with the number of participants in that study, and subse-
quently, all thus obtained products were added up and
divided by the total number of participants in all included
studies to obtain a pooled mean. For percentages of
dichotomous variables of the different studies, a compa-
rable method was applied. Because of variation in the
studies regarding reporting an overall mean or median for
the specified endpoint, the mean percentages and weighted
means are based on either mean or median of the reporting
studies. Furthermore, ranges are used to show the minimum
and maximum of the reported means or medians in the
different studies. For comparing numeric variables of low-
and high-volume centres, an independent T test was used.
Review Manager version 5.3.5 (2014) was used to calculate
the risk difference of dichotomous outcomes of the com-
parative studies and to make forest plots. To account for
clinical heterogeneity, the random effects model based on
DerSimonian and Laird’s method were used. A
p value\0.05 was considered statistically significant.
Quality assessment: MINORS instrument
Quality assessment of the included articles was performed
using the MINORS instrument, an index for the assessment
of non-randomised studies [26]. A total of eight items are
scored for non-comparative studies and 12 for comparative
studies. The items are scored 0 (not reported), 1 (reported
but inadequate) or 2 (reported and adequate). The global




The literature search identified a total of 3489 articles
(EMBASE n = 2132, PubMed n = 1314 and Cochrane
Library n = 43). A total of 1581 duplicates were removed,
and 1743 articles were excluded after screening title and
reading abstract (performed by both CD and AT), leaving
165 articles for full-text review. Finally, 33 articles fulfilled
all the inclusion criteria and met no exclusion criteria and
were included for analyses [1, 15–18, 27–54]. These 33
articles comprised 3 case reports, 25 case series and 5
comparative studies (Fig. 1). The mean MINORS index of
the non-comparative studies was 13 (range 8–15) and of
the comparative studies 20 (range 20–21), indicating fair
overall quality of the included articles. To correct for
overlapping patient populations, 9 of these studies were not
included in the overall analysis (Table 1).
Patient and tumour characteristics
In total, 794 patients were included, ranging from 1
patient to 140 patients per study. The tumour distance
was measured from the anal verge in 24 studies, in 6
from the anorectal junction and in 3 from the dentate
line. With correction for overlapping studies, in total 661
patients were included [444 males (67%) and 217
females (33%)] The calculated distance from the anal
verge ranged from 2.0 cm to 8.4 cm with a weighted
mean of 6.3 cm. Other baseline and tumour characteris-
tics are shown in Table 2.
Fig. 1 Flow chart of selection process
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Table 1 Details of included studies
Author Year of
publication








Syllaa 2010 1 0 1 20 76 NR 8
Dumont 2012 4 4 0 23.4 66.8 NR 5.3
Zorrona 2012 2 1 1 NR 65 1 7
Lacya 2013 3 1 2 21.7 73 NR 9.7
Lacya 2013 20 11 9 25.3 65 2 6.5
Sylla 2013 5 3 2 25.7 48.6 NR 5.7
Velthuisa 2013 5 2 3 NR 69.4 NR 6
Rouanet 2013 30 30 0 26 65 NR 5
Zhang 2013 1 0 1 20 48 NR 7
Fernandez-Heviaa 2014 37 24 13 23.7 64.5 2 5.8
Velthuisa 2014 25 18 7 25 64 NR 8
Atallaha 2014 20 14 6 24 57 2 5
Chouillard 2014 16 6 10 27.9 57.7 2 8.4
Meng 2014 3 2 1 NR 80 NR 6.2
Zorron 2014 9 5 4 NR 62.6 1 7.56
Veltcamp Helbach 2015 80 48 32 27.5 66.5 NR 7.2
Tuech 2015 56 41 15 27 65 2 4
Muratore 2015 26 16 10 26.2 65.8 NR 4.4
Elmore 2015 6 2 4 25 61.3 2 5.5
Knol 2015 10 8 2 26.5 60.5 NR 6.89
Serra-Aracil 2015 32 24 8 25 68 2 8
Lacy 2015 140 89 51 25.2 65.5 2 7.6
Perdawood 2015 25 19 6 28 70 2 8
McLemore 2015 1 1 0 32 66 NR 2
Buchsa 2015 20 14 6 27.1 59.3 2 6
Chen 2015 50 38 12 24.2 57.3 2 5.8
Prochazka 2015 17 11 6 28 68 3 6.0
Rink 2015 24 18 6 25 57 2 5
Burke 2016 50 30 20 26 56.5 2 4.4
Rasulov 2016 22 11 11 26 56 NR 6.5
Marks 2016 4 1 3 26 56 NR 5.1
Foo 2016 10 5 5 23.4 62.2 2 5.1











pT3? (%) Harvested lymph
nodes (N)
Syllaa 2010 1 0 100 0 0 0 23
Dumont 2012 4 0 c 0 0 NR 16
Zorrona 2012 2 0 c 0 0 100 11.5
Lacya 2013 3 0 c 0 0 66.7 NR
Lacya 2013 20 0 c 0 0 NR 15.9
Sylla 2013 5 0 100 0 0 0 33
Velthuisa 2013 5 NR 100 0 0 40 12
Rouanet 2013 30 6.7 100 0 0 100 12
Zhang 2013 1 0 100 0 13.3 70 13
Fernandez-Heviaa 2014 37 0 91.9 NR 0 62.2 14.3
Velthuisa 2014 25 NR 96 NR 4 NR 14
Atallaha 2014 20 NR 55 5 5 55 22.5













pT3? (%) Harvested lymph
nodes (N)
Chouillard 2014 16 6.3 NR 0 0 50.1 21
Meng 2014 3 0 NR 0 0 66.7 NR
Zorron 2014 9 22 b 0 11 66.7 13
Veltcamp
Helbach
2015 80 5 88.8 0 2.5 52.5 14
Tuech 2015 56 5.4 83.9 0 5.4 39.3 12
Muratore 2015 26 0 88.5 0 0 30.8 8
Elmore 2015 6 0 100 0 0 50 32
Knol 2015 10 0 90 0 0 40 10.5
Serra-Aracil 2015 32 0 93.8 0 0 NR 15
Lacy 2015 140 0 97.1 0 6.4 NR 14.7
Perdawood 2015 25 0 80 NR 4 68 21
McLemore 2015 1 0 100 NR NR 0 13
Buchsa 2015 20 15 80 0 5.9 25 23.3
Chen 2015 50 2 NR NR 4 NR 16.7
Prochazka 2015 17 0 47.1 0 11.8 35.3 10
Rink 2015 24 NR 91.67 0 8.3 33.3 14
Burke 2016 50 2.2 72 2 4.0 50 18
Rasulov 2016 22 4 68 NR 5.0 23 17
Marks 2016 4 0 100 0 0.0 25 6
Foo 2016 10 10 60 0 0.0 NR 15.6
Buchs 2016 40 7.5 92.5 0 5.0 32.5 20
Author Year
publication
N Hospital stay (days) Post-operative complications (%) 30-Day
mortality (%)
Minorf Majorf
Syllaa 2010 1 4 0 0 0
Dumont 2012 4 13 0 25 0
Zorrona 2012 2 6 50 0 0
Lacya 2013 3 4.7 33.3 0 0
Lacya 2013 20 6.5 20 0 0
Sylla 2013 5 5.2 60 0 0
Velthuisa 2013 5 NR 40 20 NR
Rouanet 2013 30 14 33.3 13.3 0
Zhang 2013 1 NR 0 0 0
Fernandez-Heviaa 2014 37 6.8 24.3 8.1 0
Velthuisa 2014 25 NR NR NR NR
Atallaha 2014 20 4.5 75 25 0
Chouillard 2014 16 NR 0 18.8 0
Meng 2014 3 6.5 0 0 NR
Zorron 2014 9 7.6 11.1 11.1 0
Veltcamp Helbach 2015 80 8 26.3 12.5 1
Tuech 2015 56 10 19.6 5.4 0
Muratore 2015 26 7 15.4 11.5 3.8
Elmore 2015 6 10.3 0 33.3 0
Knol 2015 10 6 20 0 0
Serra-Aracil 2015 32 8 18.8 25 0
Lacy 2015 140 6 36.4 10 0
Perdawood 2015 25 5 28 24 0
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Surgical details
The operative time ranged from 166 to 369 min with a
weighted mean of 243.9 min. In nine of the 33 studies, two
surgical teams performed the surgery in some or all of the
cases: one for the laparoscopic abdominal approach and
one for the transanal approach, working simultaneously.
For studies reporting on TaTME with two teams, the
weighted mean for the operative time was 209.8 min
(range 166–369) compared to 264.5 min (range 204–360)
with one operating team. Other surgical details are depicted
in Table 3.
Procedure related complications
In 18 studies, no intra-operative complications were
reported, in one study no major complications were not
reported, and in two studies the number of intra-operative
complications was not mentioned. Of the 12 studies that
did report intra-operative complications, five patients
experienced side wall damage and five patients urethral
damage during surgery. In two patients, the urethral lesion
was repaired with sutures during the procedure not result-
ing in any documented problems postoperatively. In one
patient, the lesion was managed non-operatively and no
long-term sequelae were documented. In the other patients
with urethral injury, the repair and outcome were not
described. In four of the patients with side wall damage, the
lesions were small without major post-operative morbidity
and in the other patient outcome was not reported. One
study reported early intraperitoneal CO2 leakage hamper-
ing the procedure. In one case, extensive pneumatosis of
the retroperitoneum and mesentery of the small bowel was
observed which stopped the procedure but did not result in
any post-operative morbidity. One patient experienced an




N Hospital stay (days) Post-operative complications (%) 30-Day
mortality (%)
Minorf Majorf
McLemore 2015 1 7 100 100 0
Buchsa 2015 20 7 25 10 0
Chen 2015 50 7.4 20 6 0
Prochazka 2015 17 9 23.5 11.8 0
Rink 2015 24 NR 12.5 12.5 0
Burke 2016 50 4.5 28 18 0
Rasulov 2016 22 8 27 0 0
Marks 2016 4 5 25 0 0
Foo 2016 10 6 20 0 0
Buchs 2016 40 7.5 27.5 12.5 0
BMI body mass index, ASA American Society of Anesthesiologists, NR not reported, TME total mesorectal excision, CRM circumferential
resection margin
a Potentially overlapping patient population
b Measured from anal verge
c % of total patients with anastomosis
d % of total patients
e Defined by Quirke
f Minor was defined as Clavien–Dindo classification I or II, and major was defined as CIII





BMI (kg/m2) 26.1 20–32
Age (years) 63.4 48–80
ASA score (mean) 2 1–3
Tumour distance (cm)a 6.3 2–8.4
cT3–T4 (%) 71.6 40–100
Neoadjuvant therapy (%) 72.5 28–100
BMI body mass index, ASA American Society of Anesthesiologists
a Measured from anal verge
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patients, bleeding occurred: in five, the source was the
pelvic side wall, in three the bleeding was located pre-
sacrally, in one patient the bleeding was the result of injury
to the iliac vessels, and in another patient the bleeding was
located at the left side of the mesorectum. Finally, in one
patient intraoperative bladder injury occurred. The defect
was closed laparoscopically and treated with a urinary
catheter for one week.
Pathology outcomes
At histopathological examination, different descriptions
were used to define the quality of the mesorectum ham-
pering accurate comparison. In the studies using the defi-
nition based on Quirke’s classification (n = 19), the
weighted mean of the quality of the mesorectum was
‘‘complete’’ in 87.6% and ‘‘nearly complete’’ in 10.9%.
Positive distal resection margins were found in 0.2% of the
patients. The rate of involvement of CRM was 4.7%. In
45.2% of the patients, a pT3 or pT4 tumour was found at
pathological examination (Table 4).
Post-operative outcomes and complications
The duration of hospital stay ranged from 4.5 to 14 days
with a weighted mean of 8.4 days. Total complication rate
was 40.3%. Complications reported were: anastomotic leak
(37), urinary retention and urinary dysfunction (26), ileus
(32), obstruction and intestinal occlusion (15), presacral
abscess and pelvic sepsis (18), increased ileostomy output
(16), blood transfusion (11), anastomotic stricture (11),
haemorrhage (6), bleeding (6), (organ cavity) surgical site
infection (8), fever (6), intra-abdominal collection (5),
colitis after ileostomy closure (4), nosocomial infection (3),
pneumonia (3), small bowel laceration (2), rectovaginal
fistula (2), resection of ischaemic conduit (2), perianasto-
motic fluid collections (2), wound infection (2), acute renal
failure (1), anastomotic fistula (1), ureteral stent placement
(1), ischaemia of the proximal limb of the colon (1), anas-
tomotic sinus (1), superficial necrosis of colostomy (1),
early adhesions (1), internal herniation (1), large haema-
toma (1), cerebral infarction (1), peritonitis (1), pelvic
haematoma (2), septic shock (1), inguinal lymphorrea (1),
myocardial infarction (1), pulmonary embolism (1), pelvic
collection (1), bilateral calf compartment syndrome (1),
prolapsing ischaemic anal mucosa (1), perineal wound
dehiscence after proctocolectomy (1), gastroparesis (1),
necrosis of descending colon due to injury to marginal
artery (1), transient paresthesia of both feet due to intra-
operative positioning (1), ascites (1), acute post-operative
pancreatitis (1), pseudomembranous colitis (1), necrosis of
stoma (1) and enterostomy-related other (1). Post-operative
complications defined as minor occurred in 29.5% (range
0–100%) and major complications occurred in 11.3%
(range 0–100%). Thirty-day post-operative mortality
occurred in two patients in two different studies, accounting
for a weighted mean of 0.3%. One patient suffered from
anastomotic leak and died after re-operation due to septic
complications. The other patient died three days after the
operation as a result of myocardial infarction (Table 3).
Long-term oncological outcomes
None of the studies had 3-year complete follow-up to
calculate 3-year disease-free survival. Five studies (in-
cluding 302 patients) reported follow-up of more than
Table 3 Surgical details and clinical outcomes
Weighted mean Range




Operative time (min) 243.9 166–369
Coloanal handsewn anastomosis (%)b 53.9 0–100
Diverting ileostomy (%)c 90.3 25–100
Colostomy (%)c 4.7 0–28
Two-team approach (%) 37.5 0–100
Hospital stay (days) 8.4 4.5–14
30-Day mortality (%) 0.3 0–3.8
a Minor was defined as Clavien–Dindo classification I or II, and
major was defined as CIII
b % of total patients with anastomosis
c % of total patients






Nearly complete 10.9 0–52.9
Incomplete 1.5 0–18
Distal resection margin involvement (%) 0.2 0–2
CRM involvement (%) 4.7 0–13.3
pT3–T4 (%) 45.2 0–100
Recurrenceb
Local (%) 4 0–16.7
Distant (%) 8.1 5.4–14
Follow-up (months) 18.9 15.1–29
TME total mesorectal excision, CRM circumferential resection
margin
a Defined by Quirke
b Only[ 12 months
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12 months. Overall time of follow-up was 18.9 months.
The local and distant recurrence rates were 4.0 and 8.1%,
respectively (Table 4). In one of these studies, five local
recurrences occurred during the follow-up period of
21 months. Another study reported two local recurrences,
as well as three lung metastases at median follow-up of
29 months. Further, ovarian metastases (1) and para-aortic
lymph node metastases (1) were reported in another study
after a mean follow-up of 23 months. Another study
reported one patient with local recurrence, eight patients
with systemic recurrences and two patients with local and
systemic recurrence at a median follow-up of 15.1 months.
Finally, one study reported two patients with local recur-
rences and seven patients who developed distant metas-
tases at a median follow-up of 15.1 months.
Comparative studies
Five of the included studies evaluated laparoscopic TME
versus TaTME in a case-matched study design. Subanaly-
sis of these five studies showed that the weighted means of
conversion were 5.4 versus 1.4% for laparoscopic TME
and TaTME, respectively. The risk difference of conver-
sion was -0.03 (95% CI -0.08 to 0.03; p = 0.33). For
post-operative complications, the weighted means were
34.0 versus 30.4%, respectively, with a risk difference of
-0.10 (95% CI -0.27 to 0.06; p = 0.22). TME com-
pleteness was reported in 75.2% in the laparoscopic TME
group and 82.8% in the TaTME group. The risk difference
was -0.01 (95% CI -0.07 to 0.05; p = 0.72). The
weighted means of involvement of CRM were 7.6% in the
laparoscopic TME group and 3.2% in the TaTME group
with a risk difference of 0.07 (95% CI -0.08 to 0.21;
p = 0.37) (Fig. 2).
Outcome in low- versus high-volume centres
The centres with a volume of B30 patients were compared
to the centres with a volume of[30 patients. Regarding
surgical details, operative time was shorter in the high-
volume centres (222.2 vs. 282.5 min) and the procedure
was more often performed with a two-team approach
compared to low-volume centres (51.3 vs. 13.7%). Fur-
thermore, the conversion rate was 4.3% in low-volume
centres and 2.7% in high-volume centres. The TME quality
was more often assessed as ‘‘complete’’ in high-volume
centres (80.5 vs. 89.7%), and CRM involvement was 4.8
and 4.5%, respectively. Overall complications were com-
parable, but the major complication rate was lower in high-
volume centres (12.2 vs. 10.5%) (Fig. 3). Long-term
oncological data revealed a local recurrence rate of 8.9
versus 2.8% and distant recurrence rate of 7.7 versus 8.1%
for the low- and high-volume centres, respectively,
although the number of patients with long-term follow-up
was limited (Table 5).
Discussion
This systematic review shows that the TaTME procedure is
feasible and safe. The technique is associated with sub-
stantial morbidity with comparable rates as reported for
laparoscopic abdominal TME. The outcome in terms of
specimen quality and CRM rate seems adequate with 87.6
and 4.7%, respectively. In addition, concern exists for the
long-term local recurrence rate which is relatively high
(4%) despite a relative short follow-up period
(18.9 months). Although numbers are insufficient to draw
real conclusions yet and no significance was reached,
subanalysis from case-matched control studies shows that
TME has substantial lower conversion rate compared with
the laparoscopic TME group. The weighted mean of the
conversion rate in laparoscopic TME was 5.4 versus 1.4%
in the TaTME group. Furthermore, specimen completeness
was higher in the TaTME group (82.8%) than in the
laparoscopic TME group (75.2%) and less patients had
involvement of CRM in the TaTME group compared with
the laparoscopic group (3.2 vs. 7.6%).
The outcome parameters seem dependent on the vol-
ume since small volume centres report longer operation
time and higher conversion rate. Furthermore, worse post-
operative outcomes (higher colostomy rate, major mor-
bidity, local recurrence rate and lower rate of complete
specimens) are observed as compared to the high-volume
cohorts.
The total morbidity of the TaTME procedure in this
systematic review is comparable with the conventional
laparoscopic TME as published in the large randomised
trials which display 37–54% total complications [2–11].
Fernandez-He´via et al. [35] showed a decrease in morbidity
including decreased rate of anastomotic leakage compared
to conventional TME surgery. This systematic review does
not clearly show advantage of the TaTME over the pub-
lished morbidity rate of LAR. One of the most frequent
complications reported was anastomotic leakage which
occurred in 37 out of 646 patients with anastomosis (5.7%).
The leakage rate compares favourably to reported leakage
rates from laparoscopic TME at approximately 10% and
this might be an advantage of the TaTME, although ran-
domised data have to be awaited [5]. New possible haz-
ardous complications for TaTME are reported, as urethral
lesions and damage of the pelvic side wall which are a
concern and need further attention in education. Further-
more, urinary disorders were reported in 26 patients (3.3%)
and pelvic abscesses/sepsis in 18 out of 794 patients
(2.3%). The reported incidence of presacral abscesses was
818 Tech Coloproctol (2016) 20:811–824
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Fig. 2 Comparative studies
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not increased compared to the abdominal TME procedure.
This is unexpected since it has been shown that increased
bacterial load is present in the pelvis after TaTME [19].
The low rate of conversions compared to reported laparo-
scopic TME seems a major improvement and might be
accounted as a benefit of TaTME. The reported colostomy
rate is very low, but no conclusions can be drawn since
considerable selection bias is present since cohort studies
do not present intention-to-treat results.
Another potential advantage of the TaTME is
improvement in oncological outcome. Surgical specimen
quality defined by (1) mesorectal completeness, (2) CRM
and (3) distal margins has been shown to be the most
important prognostic factor predicting local recurrences
[55]. Due to better visualisation in the deep pelvis, metic-
ulous resection can be performed. Cohort and case series of
TaTME for rectal cancer included in this systematic review
have shown that 2.2% of the specimens were judged as
incomplete. In 87% of the cases, the resected specimens
were considered intact. In two of the largest randomised
trials concerning laparoscopic rectal cancer surgery, the
reported rates of complete specimens were 72 and 88%
[2, 5]. Another potential improvement in oncological out-
come after TaTME is decrease in involvement of CRM.
The average involved CRM rate after laparoscopic
abdominal rectal resection in large randomised trials
including TME is 6–8% [2–10]. This systematic review
shows an involved CRM rate of 4.3% after TaTME. CRM
is a most significant prognostic factor for local recurrences
and might relate to the expertise of the surgeon. Positive
distal resection margins were found in 0.3% of the patients.
These objective surgical quality measurements compare
favourably to the published surgical laparoscopic rectal
cancer studies, especially since the majority of the data are
obtained from mid and low rectal cancer, whereas the large
laparoscopic trials include low, mid and high rectal cancers
[2–10]. It is debatable whether these data from cohort
series can be compared to an audited clinical (randomised)
trial. Nevertheless, TaTME potentially shows benefits over
the laparoscopic TME regarding these oncological
outcomes.
In the major trials investigating laparoscopic surgery for
rectal cancer, the local recurrence rate for mid and low
rectal cancer is approximately 5% after three years
Fig. 3 Comparison of low- versus high-volume centres
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[6–8, 11]. The local recurrence rate as shown in this sys-
tematic review is 4%. However, this number is likely an
underestimation due to the inadequate length of follow-up
(18.9 months) and inadequate number of studies reporting
follow-up. Interestingly, the involved CRM rate was sim-
ilar to the local recurrence rate. Concern regarding intra-
luminal spread or other unknown factors exist, but it has to
be noted that due to inadequate numbers and lack of long-
term oncological follow-up preferably from randomised
data no conclusions can be drawn.
This systematic review evidently shows a relationship
between case volume and outcomes. Higher-volume cen-
tres have better outcome compared to small volume cen-
tres. Although statistical significance could not be obtained
since lack of original data including standard deviations, a
clear trend is visible. Operative time and conversion rate
were lower, and the use of two simultaneous teams for the
abdominal phase and the transanal phase during TaTME
was performed more frequently in the high-volume centres
compared to small volume centres. More interestingly,








Conversion (%) 4.3 2.7
Post-operative complications (%): minorf 21.9 25.2
Post-operative complications (%): majorf 12.2 10.5
TME quality (%): completed 80.5 89.7
TME quality (%): nearly completed 15.1 9.0
TME quality (%): incompleted 4.0 1.3
Distal resection margin involvement (%) 0.4 0.3
CRM involvement (%) 4.8 4.5
pT3–T4 (%) 44.3 45.1
Gender M (%) 65.8 67.4
Gender F (%) 34.2 32.6
BMI (kg/m2) 26.1 26.0
Age (years) 62.3 63.8
ASA score (mean) 2 2
Tumour distance (cm)a 6.0 6.5
cT3–T4 (%) 71.3 69.3
Neoadjuvant therapy (%) 69.8 73.0
Operative time (min) 282.5 222.2
Coloanal handsewn anastomosis (%)b 62.6 46.8
Diverting ileostomy (%)c 89.8 88.8
Colostomy (%)c 6.8 4.8
Two-team approach (%) 13.7 51.3
Hospital stay (days) 6.6 6.5
30-Day mortality (%) 0.4 0.2
Recurrence: local (%)e 8.9 2.8
Recurrence: distant (%)e 7.7 8.1
Follow-up (months)e 21.9 18.3
TME total mesorectal excision, CRM circumferential resection margin, BMI body mass index, ASA
American Society of Anesthesiologists
a Measured from anal verge
b % of total patients with anastomosis
c % of total patients
d Defined by Quirke
e Only[ 12 months
f Minor was defined as Clavien–Dindo classification I or II, and major was defined as CIII
Tech Coloproctol (2016) 20:811–824 821
123
both quality of the resection and post-operative outcome
were better in high-volume centres. However, an actual
learning curve could not be extracted from the included
studies, as a proficiency curve has yet to be determined and
individual rates of series and outcomes were unavailable.
These data reflect the relative difficulty of the procedure
requiring multiple skills including single-incision laparo-
scopic surgery (SILS) technique and two-team operating.
As is known from colon surgery and oesophageal surgery,
higher volume is associated with better outcomes [25]. For
TaTME, this equation seems equal to the other difficult
procedures. Although the quality of the data is non-ran-
domised, this difference seems valid and calls for educa-
tion, training and proctoring in order to have a safe
introduction of the TaTME technique. A well-designed
trial in which surgical quality assurance is an essential
component should be ideal to evaluate the potential benefit
of the TaTME technique. Before entering the trial, a sur-
geon should be trained and proctored and its surgical per-
formance should be objectively monitored in order to
exclude underperformance within the trial.
A major limitation of the available data is the lack of
randomised evidence. Current cohort data are the result of
the pioneers. The TaTME technique is technically
demanding of both surgeon and team and requires a
learning curve. Another limitation of this and previous
systematic reviews is that the included studies are hetero-
geneous concerning clinical and tumour characteristics,
surgical details and reporting of complications. Therefore,
comparison of these studies and outcomes of this review
should be carefully interpreted. Moreover, most of the
studies include same patients in different reports.
Abstracts, congress supplements and other unpublished
data were not included with the aim to exclude major bias
in contrast to previous published reviews. Furthermore, in
the low- versus high-volume analysis, all (partial) duplicate
publications were excluded. Nonetheless, most papers
represent a small number of patients and high-quality
studies are lacking. In the absence of published data con-
cerning a learning curve or number of cases to achieve
proficiency, we choose to use a cut-off point of 30 based on
the traditional rectal surgery and agreement of the con-
sensus group. We realize that this subanalysis is prone to
bias. Furthermore, the majority of the studies exclude
tumours with ingrowth in surrounding tissues. Especially,
rectal cancer surgery in patients with T4 tumours is chal-
lenging and needs improvement, in specific regarding the
quality of the resected specimen. Finally, adequate follow-
up period of most studies is lacking and hampering any
firm conclusions about long-term outcome.
Nevertheless, even at this early stage of implementation
of the TaTME technique, it is important to provide a crit-
ical overview of the experience and outcomes of the
procedure worldwide and especially to highlight the tech-
nical difficulty and possible hazardous aspects of TaTME.
The TaTME consensus group has stated that at least 14
procedures a year have to be performed in order to assure
optimal quality of the procedure [56]. To ensure save
implementation and consistency in surgical quality, several
TaTME expert centres across Europe and the USA provide
training workshops and facilitate proctoring of the tech-
nique. Within the context of a future randomised controlled
trial, quality assurance of this new technique seems of
paramount importance.
In conclusion, TaTME is a potentially advantageous
procedure for mid and low rectal cancer. Despite the cur-
rent data available is mainly based on expert centres,
considerable morbidity has been reported. In order to avoid
unwanted negative outcome associated with widespread
uncontrolled use of this novel technique, quality assurance
and controlled safe implementation seem essential. TaTME
has high potential; however, extensive evaluation in a well-
designed multicentre randomised trial is needed to come to
unequivocal conclusions.
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